Goserelin (Zoladex) has brought good news to patients who need to treat diseases such as prostate cancer, breast cancer and endometriosis. As a synthetic luteinizing hormone-releasing hormone (GnRH) analog, it effectively regulates male serum testosterone and female serum estradiol levels by inhibiting the secretion of luteinizing hormone from the pituitary gland to achieve the therapeutic purpose. This article will briefly introduce the precautions and treatment effects of Goserelin.

Precautions

1. Women with reproductive potential and pregnancy

Before starting treatment with Goserelin, pregnancy must be excluded for women using Goserelin to treat benign gynecological diseases, and women of reproductive potential should be advised to avoid pregnancy during treatment.

2. Tumor flare phenomenon

During the first few weeks of Goserelin treatment, there may occasionally be a brief worsening of symptoms or other signs and symptoms of prostate cancer or breast cancer. A small number of patients may experience temporary bone pain, which can be treated symptomatically.

3. Hyperglycemia and diabetes

Hyperglycemia may represent the development of diabetes or worsening of blood sugar control in diabetic patients. In patients treated with GnRH agonists, blood glucose and glycated hemoglobin need to be monitored regularly and managed according to current practices for the treatment of hyperglycemia or diabetes.

4. Cardiovascular disease

The use of GnRH agonists in men increases the risk of myocardial infarction, sudden cardiac death, and stroke. When determining treatment options for patients with prostate cancer, cardiovascular risk factors should be carefully evaluated. Patients treated with GnRH agonists should be monitored for symptoms and signs suggestive of the development of cardiovascular disease and managed according to current clinical practice.

5. Hypercalcemia

Some patients with prostate cancer and breast cancer bone metastases develop hypercalcemia after starting treatment with Goserelin. If hypercalcemia does occur, appropriate treatment measures should be taken.

For more details on precautions, please refer to the instructions.

Therapeutic effect of Goserelin

1. Trial design

The effect of Goserelin was clearly demonstrated in an experiment conducted by the Early Breast Cancer Trialists' Collaborative Group. The value of ovarian suppression using luteinizing hormone-releasing hormone analogs has been demonstrated in a series of studies involving more than 8,000 patients.

2. Setting of trial results

Currently, standard adjuvant therapy for premenopausal women with early breast cancer includes oophorectomy by surgery or radiotherapy, chemotherapy, and tamoxifen. The use of Goserelin to treat early breast cancer provides an option that avoids the side effects of cytotoxic chemotherapy and may provide unique benefits to premenopausal patients.

3. Trial results

The results of these studies provide evidence that Goserelin, alone or in combination with tamoxifen, is at least as effective as cytotoxic chemotherapy for patients with hormone receptor-positive tumors and is also effective when used after adjuvant chemotherapy.

In addition, no formal drug-drug interaction studies were conducted. There are no confirmed reports of interactions between Goserelin and other drugs. Goserelin should be stored at room temperature, not exceeding 25°C.

【Tips】The instructions for some products are frequently changed, please refer to the actual product.